Skip to content

Public FDA record

Z-0328-2025: BioZorb Marker. Radiographic soft tissue marker.

Recall record Z-0328-2025 for Hologic, Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0328-2025
Company in FDA record
Hologic, Inc
FDA classification date
Nov 26, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

Firm received reports of adverse events/complications that include serious injuries, such as pain, infection, rash, device migration, device erosion, seroma, and discomfort.

Source facts

Action
Consignees were sent an URGENT: MEDICAL DEVICE RECALL letter by mail dated 10/24/24. The notification instructs consignees to quarantine all affected devices and share the recall notification with all surgeons in their practice that have used or planned to use the BioZorb Marker. Additionally, if product was further distributed the notice is to be forwarded to those customers. Affected devices will be returned to Hologic and coordination of return will be initiated by return of the Customer Response Form. Healthcare providers are recommended to be aware of reports of serious adverse events following the placement of the BioZorb Marker devices in breast tissue and to continue to monitor patients for signs of any adverse events. BioZorb Markers are not cleared to fill space in the tissue or improve cosmetic outcomes after procedures. Patients are recommended to contact their healthcare provider if they experience any adverse events following the placement of their BioZorb marker. Hologic states that there is no need to undergo explantation of the device unless advised by your healthcare provider. Patients who have received the BioZorb Marker and/or your provider is planning radiation therapy treatments, discuss the possible risks with your provider. Report any problems/complications and direct any questions regarding this recall to Hologic at breasthealth.support@hologic.com. ***Update May 5, 2026: On April 6, 2026 A Follow-up notification as an updated resource for clinicians who have previously used Biozorb breast markers or are currently caring for patients implanted with BioZorb markers. Hologic recalled and removed from market BioZorb and BioZorb LP on October 24, 2024; therefore, all patients with these implants have had them in place for at least one year. The original notification that was distributed as a part of the previous recall can be found as an appendix to this resource.
Initiated
2024-10-10
Root cause
Device Design
Distribution
Domestic: US Nationwide Distribution.
Recall number
Z-0328-2025
Recall status
Open, Classified
CDRH record ID
210848
FDA classified
2024-11-26
Recall event number
95639

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗